Cosentyx (secukinumab) — United Healthcare
moderate to severe hidradenitis suppurativa
Initial criteria
- Diagnosis of moderate to severe hidradenitis suppurativa
- Patient is not receiving Cosentyx in combination with another targeted immunomodulator [e.g., adalimumab, Bimzelx (bimekizumab-bkzx)]
Reauthorization criteria
- Documentation of positive clinical response to Cosentyx therapy
- Patient is not receiving Cosentyx in combination with another targeted immunomodulator [same list as above]
Approval duration
12 months